|
|
Blood, Vol. 110, Issue 6, 2067-2074, September 15, 2007
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms
Blood Parekh et al.
110: 2067
Supplemental materials for Parekh et al, Vol. 110, Issue 6, 2067-2074
Files in this Data Supplement:
- Figure S1. A second MTA3 siRNA also induces differentiation but not toxicity in DLBCL cells (PDF, 512 KB) -
(A) MTA3 was depleted by siRNA #2 in Ly1 cells and SUDHL4 cells and the MTA3, PRDM1, SDC1, TP53, and ATR transcripts measured after 48 hours by QPCR. (B) Ly1 and SUDHL4 cells depleted with MTA3 siRNA #2 were subjected to immunoblotting with PRDM1, MTA3, and actin antibodies. (C) Densitometry was performed in the immunoblot shown in panel B. (D) LY1 cells were depleted of MTA3 depletion by by siRNA #2 and subjected to immunohistochemistry for MTA3, PRDM1, and kappa light chains. (D) MTA3 siRNA #2 or control were transfected in SUDHL4 cells, which were then exposed to BPI. Cell viability was measured by reduction of rezasurin at 48 hours.
- Figure S2. Effect of MTA3 depletion on additional BCL6 targets (PDF, 11.6 KB) -
MTA3 was depleted in LY1 cells as described. Real time PCR was performed for the Cyclin D2, MIP1a, CD69 (CCL3), PDCD2, p21(CDKN1A) and p27. The Y-axis represents fold change in gene expression calculated as described in “Materials and methods, Real Time PCR.”
- Figure S3. Effect of MTA3 depletion on SUDHL4 cells (PDF, 24.2 KB) -
MTA3 was depleted in SUDHL4 cells as described in “Materials and methods, SiRNA gene knockdown.” SUDHL4 cells were depleted of MTA3 by siRNA #1 and subjected to immunohistochemistry for MTA3, PRDM1 and kappa light chains.
- Table 1. Primers used for QPCR and QChIP (XLS, 14.5 KB)
- Table S2. Blimp array (XLS, 342 KB)
-
The table details the design of the genomic tiling array used for ChIP-on-chip, including the sequence and location of each probe. These correspond to the PRDM1 and GAPDH loci. The table also indicates the fold enrichment yielded by each probe after immunoprecipitation with BCL6 or actin antibodies. The probes corresponding to the newly identified BCL6 binding region in intron 3 are highlighted in yellow. The GAPDH locus displayed minimal enrichment of a few probes that is highly unlikely to represent a true signal.
- Table S3. Antibodies and probes for immunohistochemistry (XLS, 16.5 KB)
| |
